Italian CDMO Olon has completed a large-scale high containment production line (OEL < 1 mg/m3) at its Rodano site at a cost of about €10 million. This is part of a planned €27 million it will roll out over 2022-3 that is fully allocated to the expansion of further internal expertise and capacity of high containment production. The new line, which is already operative, enables Olon to produce HPAPIs in batches of 30-250 kg.
Italian CDMO Olon has reached a long-term strategic partnership for the manufacturing of the protein-based biocontrol products of Belgium’s Biotalys. This, the companies said, will secure the global supply of Biotalys’ first product, Evoca, a biofungicide that is planned for market introduction in the US in 2H 2022, subject to regulatory approval.
At CPhI Worldwide 2021 in Milan on 9-11 November, Italian CDMO Olon announced “a significant expansion of its pipeline of APIs, a result of its R&D investment strategy”. In all, it has added nine new active substances for the generics market by investing across several lines and at multiple facilities in its network.
In partnership with Aguettant Pharmarmaceutical, Italy’s Olon Group is to expand and renovate its plant in Mulazzano, which is dedicated to the production by enzymatic transformation. It will install reactors, filters and ancillary equipment, as well as automating and digitalising some steps performed there.
During its 2020 results presentation, Italian API producer Olon announced the completion of a large-scale, multi-purpose, high-containment HPAPI production line at its Rodano site near Milan. This is already available to customers, the firm added.
Italian CDMO and generic API maker Olon has acquired its compatriot CapuaBioservices, which provides
